November 21, 2012
With Amarin's (Nasdaq: AMRN ) new triglyceride-lowering drug Vascepa approved and potentially ready for launch starting in 2013, some decisions have to be made now about how the drug is going to be marketed -- and who's going to do it. Many investors want to see a buyout so that a drugmaker with a larger marketing department can more easily promote Vascepa. However, with the drug's new chemical entity, or NCE, status still up in the air, it seems as though buyout negotiations are on hold. This means that Amarin might be launching this drug on its own. In this video, health care analysts Max Macaluso and David Williamson discuss why shareholders are hoping for a buyout and some of the risks that many small and mid-sized pharma companies face when marketing new therapeutics.
The biotech space can make or break investors ovnight, and while Amarin certainly won't fold if it isn't bought out, the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.